Article révisé par les pairs
Titre :
  • Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: A drug review
Auteur : Polastro, Laura L. ; Aftimos, Philippe ; Awada, Ahmad
Informations sur la publication : Expert review of anticancer therapy, 14, 6, (page 649-665)
Statut de publication : Publié, 2014
Sujet CREF : Cancérologie
Pharmacologie
Mots-clés : breast cancer
chemotherapy
eribulin
review
solid tumor
Mots-clés MeSH : Alopecia -- chemically induced
Antineoplastic Agents -- adverse effects -- pharmacology -- therapeutic use
Breast Neoplasms -- drug therapy
Carcinoma -- drug therapy -- secondary
Chemotherapy, Adjuvant
Clinical Trials as Topic
Drug Approval
Drug Resistance, Neoplasm
Drugs, Investigational
Ethers, Cyclic -- pharmacology
Fatigue -- chemically induced
Female
Furans -- adverse effects -- chemistry -- pharmacology -- therapeutic use
Humans
Ketones -- adverse effects -- chemistry -- pharmacology -- therapeutic use
Macrolides -- pharmacology
Molecular Targeted Therapy
Multicenter Studies as Topic
Neoadjuvant Therapy
Neutropenia -- chemically induced
Peripheral Nervous System Diseases -- chemically induced
Tubulin Modulators -- adverse effects -- chemistry -- pharmacology -- therapeutic use
United States
United States Food and Drug Administration
Note : SCOPUS: re.j
Langue :
  • Anglais
Identificateurs : urn:issn:1473-7140 
info:doi/10.1586/14737140.2014.920693
info:pmid/24852360